

Recombinant Human VEGFR3/FLT4 Protein (His Tag)

Catalog Number: PKSH031419

Note: Centrifuge before opening to ensure complete recovery of vial contents.


Description

Species	Human
Source	HEK293 Cells-derived Human VEGFR3/FLT4 protein Met 1-Ile 776, with an C-terminal His
Calculated MW	86.0 kDa
Observed MW	130 kDa
Accession	NP_002011.2
Bio-activity	Measured by its binding ability in a functional ELISA. Immobilized human VEGF-C at 10 µg/mL (100 µl/well) can bind human VEGFR3-his. The EC ₅₀ of human VEGFR3-his is 0.011 µg/mL. Measured by its ability to bind human VEGF-D in a functional ELISA.

Properties

Purity	> 97 % as determined by reducing SDS-PAGE.
Endotoxin	< 1.0 EU per µg of the protein as determined by the LAL method.
Storage	Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80 °C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.
Shipping	This product is provided as lyophilized powder which is shipped with ice packs.
Formulation	Lyophilized from sterile PBS, pH 7.4 Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization. Please refer to the specific buffer information in the printed manual.
Reconstitution	Please refer to the printed manual for detailed information.

Data



> 97 % as determined by reducing SDS-PAGE.

Background

For Research Use Only

Toll-free: 1-888-852-8623
Web: www.elabscience.com

Tel: 1-832-243-6086
Email: techsupport@elabscience.com

Fax: 1-832-243-6017

Rev. V3.5

Vascular endothelial growth factor receptor 3 (VEGFR3), also known as FLT-4, together with the other two members VEGFR1 (FLT-1) and VEGFR2 (KDR/Flk-1) are receptors for vascular endothelial growth factors (VEGF) and belong to the class III subfamily of receptor tyrosine kinases (RTKs). The VEGFR3 protein is expressed mainly on lymphatic vessels but it is also up-regulated in tumor angiogenesis. Mutations in VEGFR3 have been identified in patients with primary lymphoedema. The VEGF-C/VEGF-D/VEGFR3 signaling pathway may provide a target for antilymphangiogenic therapy in prostate cancer, breast cancer, gastric cancer, lung cancer, non-small cell lung cancer (NSCLC), and so on.